Register for THE 2024 Achondroplasia & Skeletal Dysplasia research conference
ACHONDROPLASIA & SKELETAL DYSPLASIA RESEARCH CONFERENCE
The Achondroplasia & Skeletal Dysplasia Research Conference, hosted by The Chandler Project, brings together patients, parents and caregivers, physicians, researchers, and pharmaceutical and biotech companies to engage and network with one another in a safe environment to openly discuss the latest research and developments surrounding pharmaceutical treatment options and advances in surgical treatment for achondroplasia and other skeletal dysplasias.
WHEN:
Friday, June 28 – Sunday, June 30, 2024
WHERE:
Royal Sonesta Harbor Court
550 Light Street, Baltimore, MD 21202
The Chandler Project
Through advocacy, The Chandler Project raises awareness of transformative research on achondroplasia and other skeletal dysplasias by supporting a global community and network of patients, parents, and caregivers seeking information on the latest pharmaceutical research & developments and advancements in surgical treatment.
The Chandler Project is mission-oriented to bringing parents & caregivers of newly diagnosed babies science from the source by connecting them with world-renowned researchers and physician experts who treat achondroplasia and other skeletal dysplasias. Click here to learn more
LATEST NEWS
achondroplasia & skeletal dysplasia RARE-X data collection program
By generating the most comprehensive Data Collection Program, YOU can help accelerate research and the development of new drugs, devices, or other therapies for achondroplasia and other skeletal dysplasias.
researching achondroplasia & other skeletal dysplasias
the following companies have or are developing pipelines for achondroplasia, other skeletal dysplasias & growth disorders
Biomarin, Qed Therapeutics, Ascendis Pharma, Tyra Biosciences, AND SANOFI ARE SPONSORS/SUPPORTERS OF THIS YEAR’S CONFERENCE. BioMarin, QED, ASCENDIS, AND TYRA have supported PAST EVENTS and PROGRAMS FOR THE CHANDLER PROJECT
NEW research from Dr. Ravi
drug may reduce sudden infant death syndrome in children with achondroplasia
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomized, double-blind, placebo-controlled, phase 2 trial
Correspondence to: Professor Ravi Savarirayan, Murdoch Children’s Research Institute, Royal Children’s Hospital, University of Melbourne, Parkville, VIC 3054, Australia
📧 ravi.savarirayan@vcgs.org.au
🫶🏻 COMMUNITY
The Chandler Project is a registered 501c3 nonprofit organization. EIN: 83-1692863
PO Box 7549
Little Rock, AR 72207